Core Insights - INmune Bio (NASDAQ: INMB) has been part of the "Bio Boom" speculative portfolio since September 2023, with no changes made to its position despite the company's progress [2] Group 1 - The company has not seen any adjustments in its investment thesis since its inclusion in the portfolio [2] - The leader of the investing group Compounding Healthcare focuses on innovative companies developing breakthrough therapies and pharmaceuticals [2] Group 2 - The analyst holds a beneficial long position in INMB shares, indicating confidence in the company's potential [3]

Core Viewpoint - Former hedge fund manager Martin Shkreli has warned of a potential 90% drop in shares of Inmune Bio Inc., a biotech startup focused on using the immune system to combat cancers, following a recent surge in its stock price [1][2]. Group 1: Stock Performance and Predictions - Shkreli predicts that Inmune Bio's stock could fall to $0.50, representing a 90.61% decline from its closing price of $5.33 on the previous Friday [2]. - The company's shares had recently surged by 44% due to investor enthusiasm surrounding its neuroinflammation candidate, XPro1595, which targets Alzheimer's disease and other central nervous system disorders [2]. Group 2: Critique of Inmune Bio - Shkreli has expressed concerns regarding the lack of robust Phase 1 trial data and the absence of peer-reviewed publications supporting the efficacy of the candidate [4]. - He criticized the study design for not including a placebo arm, which complicates the assessment of whether observed improvements are due to the drug or a placebo effect [4]. - BMF Reports, an activist short-seller, has echoed Shkreli's concerns, highlighting flawed science, questionable trial designs, and accounting improprieties, including payments to "ghost consultants" [5]. Group 3: Market Reaction - Following Shkreli's warning, Inmune Bio's shares fell by 15.13% on Friday and continued to decline by 16.32% in after-hours trading [7].

Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds from the Offering are approximately $19 million, before deducting placement a ...

INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro. The company announced results from its Phase 2 MINDFuL trial evaluating XPro, a selective soluble TNF inhibitor, in early Alzheimer's Disease with biomarkers of inflammation. Also Read: Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion Despite showing no effects in the modified inten ...

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. Treatment with XPro™ was well-tolerated and safe, eve ...

Conference Call Today at 4:30pm ETBOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. Q1 2025 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the secon ...

2025 年 05 月 05 日 智能眼镜引领产业发展新优势,AI PC 紧跟 PC 智 能化浪潮 买入(首次) 投资要点 分析师：高永豪 S1050524120001 gaoyh7@cfsc.com.cn 联系人：张璐 S1050123120019 zhanglu2@cfsc.com.cn | 基本数据 | 2 0 2 5-0 4-3 0 | | --- | --- | | 当前股价（元） | 32.98 | | 总市值（亿元） | 33 | | 总股本（百万股） | 100 | | 流通股本（百万股） | 99 | | 52 周价格范围（元） | 11.6-45 | | 日均成交额（百万元） | 177.41 | 市场表现 100 150 200 250 (%) 雷神科技 沪深300 -50 资料来源：Wind，华鑫证券研究 相关研究 —雷神科技（872190.BJ）公司动态研究报告 ▌ AI 智能眼镜延伸视觉，打开人类与数字世界交 互的入口 公司持续布局智能产品，在 2025 国际眼镜业展览会上，公司 就曾展出过三款基于不同技术原理的产品——雷神 AURA 智能 眼镜 AI 探索版、雷神 AURA 智能 ...

2025 年 05 月 05 日 智能眼镜引领产业发展新优势,AI PC 紧跟 PC 智 能化浪潮 买入(首次) 投资要点 分析师：高永豪 S1050524120001 gaoyh7@cfsc.com.cn 联系人：张璐 S1050123120019 zhanglu2@cfsc.com.cn | 基本数据 | 2 0 2 5-0 4-3 0 | | --- | --- | | 当前股价（元） | 32.98 | | 总市值（亿元） | 33 | | 总股本（百万股） | 100 | | 流通股本（百万股） | 99 | | 52 周价格范围（元） | 11.6-45 | | 日均成交额（百万元） | 177.41 | 市场表现 100 150 200 250 (%) 雷神科技 沪深300 -50 资料来源：Wind，华鑫证券研究 相关研究 —雷神科技（872190.BJ）公司动态研究报告 ▌ AI 智能眼镜延伸视觉，打开人类与数字世界交 互的入口 公司持续布局智能产品，在 2025 国际眼镜业展览会上，公司 就曾展出过三款基于不同技术原理的产品——雷神 AURA 智能 眼镜 AI 探索版、雷神 AURA 智能 ...